Aprotinin and dipyridamole for the safe reduction of postoperative blood loss

Annals of Thoracic Surgery

Volumn 65, Issue 3, 1998, Pages 674-683

  Cohen, Gideon ^a   Ivanov, Joan ^a   Weisel, Richard D ^a   Rao, Vivek ^a   Mohabeer, Molly K ^a   Mickle, Donald A G ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; APROTININ; DIPYRIDAMOLE; FIBRINOGEN; HEMOGLOBIN; HEPARIN; PLACEBO; PLASMINOGEN; PROTAMINE SULFATE; PROTHROMBIN; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT PATENCY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEART VALVE REPLACEMENT; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME;

APROTININ; BLOOD COAGULATION; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032033612     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)01428-8     Document Type: Article

References (25)

1. Rao V, Christakis GT, Weisel RD, et al. The changing pattern of valve surgery. Circulation. 94:(suppl 2):1996;113-120.
2. Rao V, Ivanov J, Weisel RD, et al. Predictors of low cardiac output syndrome following coronary artery bypass. J Thorac Cardiovasc Surg. 112:1996;38-51.
3. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high dose tranexamic acid. J Thorac Cardiovasc Surg. 110:1995;835-842.
4. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost. 13:1987;50-68.
5. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 55:1993;1033-1041.
6. Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 44:1987;640-645.
7. Bidstrup BP, Royston D, Sapsford R, Taylor K. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin. J Thorac Cardiovasc Surg. 97:1989;364-372.
8. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization a placebo-controlled study . Ann Thorac Surg. 54:1992;1031-1038.
9. Saffitz JE, Stahl DJ, Sundt TM, Wareing TH, Kouchoukos NT. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest. Am J Cardiol. 72:1993;1080-1082.
10. Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg. 55:1993;1418-1424.
11. Chesebro JH, Clements IP, Fuster V, et al. A platelet inhibitor drug trial in coronary artery bypass operations benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein graft patency . N Engl J Med. 307:1982;73-78.
12. Fremes SE, Levinton C, Naylor CD, et al. Optimal antithrombotic therapy following aortocoronary bypass a meta-analysis . Eur J Cardiothorac Surg. 7:1993;169-180.
13. Teoh KH, Christakis GT, Weisel RD, et al. Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 96:1988;332-341.
14. Clauss VA. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol. 17:1957;237-246.
15. Hosmer DW, Lemeshow S. Applied logistic regression. 1989;John Wiley & Sons, New York.
16. Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med. 12:1986;1-7.
17. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJ. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass. Acquired transient platelet dysfunction associated with selected alpha granule release. Blood. 56:1980;824-834.
18. Edmunds LH, Ellison N, Colman RW. Platelet function during cardiac operation. Comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg. 83:1982;805-812.
19. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med. 314:1986;1446-1448.
20. Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 97:1989;235-239.
21. Wildevuur CRH, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg. 3:1989;533-538.
22. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 65:1985;32-40.
23. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature. 286:1980;456-460.
24. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects the platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;788-797.
25. Coleman RW, Scott CF, Schmier AU, et al. Initiation of blood coagulation at artificial surfaces. Ann NY Acad Sci. 56:1987;253-267.